emtricitabine/tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

Hearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study. (PubMed, Pediatr Infect Dis J) - "While SNHL was relatively common, there were no consistent associations between in utero ARV exposure and SNHL or incomplete DPOAEs. Further research is needed on ARV exposures and other hearing measures in CHEU."

Journal • Human Immunodeficiency Virus • Infectious Disease • Otorhinolaryngology

Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition. (PubMed, JAMA Netw Open) - "Retrospective observational cohort study from January 2021 to December 2023 using US pharmacy claims data from HIV-1-negative adults who received daily oral brand emtricitabine and tenofovir disoproxil fumarate (F/TDF), generic F/TDF (gF/TDF), or emtricitabine and tenofovir alafenamide fumarate (F/TAF), or intramuscular injection of cabotegravir every 2 months, for PrEP (after a 180-day washout period for previous PrEP use). In this cohort study, HIV-1 incidence was higher in individuals with abandoned or rejected PrEP claims compared with those with dispensed claims. These findings highlight the importance of targeted strategies to improve PrEP claim dispensation and remove payer barriers to reduce HIV-1 transmission."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Daily PrEP and Event Driven PrEP adherence for men who have sex with men in China. (PubMed, Sex Health) - "We observed a higher adherence to daily PrEP compared to Event Driven-PrEP among a sample of MSM in China. Further research is needed to examine long-term PrEP adherence among MSM in China."

Journal • Human Immunodeficiency Virus • Infectious Disease

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update. (PubMed, CMAJ) - "Multiple safe, effective PrEP and PEP regimens are now available in Canada, making it increasingly possible to find suitable options for all who could benefit. Implementation of this guideline should expand access to biomedical HIV prevention interventions for those at risk and decrease the incidence of HIV in Canada."

Clinical guideline • Journal • Human Immunodeficiency Virus • Infectious Disease

Diagnosis of HIV infection during pregnancy: Trends from a national cohort in Spain. (PubMed, HIV Med) - "Among women diagnosed with HIV during pregnancy, half were late presenters, and one-third were diagnosed after the first trimester, with higher percentages among African and Latin American women. There was a high proportion of caesarean deliveries. Most women initiated ART promptly after cohort enrolment and achieved undetectable VL at the end of pregnancy."

Journal • Human Immunodeficiency Virus • Infectious Disease

Clinical Characteristics of Tuberculosis Among People Living with Human Immunodeficiency Virus (HIV): A Multicenter Study. (PubMed, J Clin Pract Res) - "The most commonly used antiretroviral treatment regimen was tenofovir disoproxil fumarate/emtricitabine/dolutegravir (TDF/FTC/DTG). The study highlighted the need for improved screening and prophylaxis for latent TB in individuals infected with HIV, especially those with low CD4+ T lymphocyte counts. The results underscore the importance of timely diagnosis and careful management of HIV-TB co-infection to reduce morbidity and mortality."

Clinical • Journal • Cough • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Vaccination uptake and associated factors among HIV pre-exposure prophylaxis (PrEP) users: insights from a retrospective cross-sectional study. (PubMed, BMC Public Health) - "Vaccination coverage among PrEP users is suboptimal. High PrEP adherence and prescriptions by family physicians are strong predictors of vaccination. These findings highlight the need for targeted interventions to enhance vaccine uptake within PrEP care settings, emphasizing the importance of continuity of care and a patient-centered approach."

Journal • Observational data • Retrospective data • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Influenza • Oncology • Respiratory Diseases

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. (PubMed, Sci Rep) - "Daily oral pre-exposure prophylaxis (PrEP), including emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy for HIV prevention. TAF-only (β = 2.532, 95%CI 0.708-4.356) and TDF-TAF (β = 2.756, 95%CI 0.890-4.621) were associated with significantly increased weight gain compared to TDF-only use. Closer monitoring of weight gain is recommended for individuals using TAF to prevent HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease

Adherence to Oral HIV Pre-exposure Prophylaxis During Pregnancy and the Post-partum Period: Lessons Learned in an Open-Labelled Clinical Trial. (PubMed, AIDS Behav) - P2/3 | "In an open-label PrEP clinical trial, adherence to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was measured using returned pill counts during pregnancy and post-delivery, up to 54 weeks. Based on TFV-DP levels, only 20% of pregnant women and 10% of postpartum women had levels suggestive of adherence greater than 80%. Lack of transparency in adherence disclosure underscores the need for real-time, objective measures of adherence to inform targeted adherence counseling.Clinical Trial Number CAP016 is on ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT03227731 )."

Journal • Human Immunodeficiency Virus • Infectious Disease

Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN). (PubMed, Trials) - P3 | "This study will provide critical data to inform scalable delivery models for both oral and injectable PrEP among mobile men at high risk for HIV acquisition. Findings will also highlight the potential of PrEP choice delivery and its benefits, offering evidence for governments to consider in the rollout of injectable PrEP in public health systems. Trial registration NCT06133686. Registered on 14 November 2023. PACTR202409632006463. Registered on 2 September 2024."

Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (clinicaltrials.gov) - P3 | N=4580 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease

'I want him to get on PrEP': the perspectives of men who have sex with men living with HIV on sexual partners' use of pre-exposure prophylaxis. (PubMed, Sex Health) - "The present study highlights the nuanced perspectives of MSMWH on the use of PrEP for HIV-negative partners. Efforts to increase uptake of PrEP may benefit from attending to interpersonal facilitators of PrEP uptake, such as partner support."

Journal • Human Immunodeficiency Virus • Infectious Disease

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (clinicaltrials.gov) - P3 | N=4390 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Oct 2027 ➔ Jul 2027 | Trial primary completion date: Oct 2027 ➔ Jul 2027

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care. (PubMed, Infect Dis Ther) - "Among Medicare-insured PWH with low adherence or significant gaps in care, those receiving B/F/TAF had a lower risk of switch compared with other ART regimens. Optimizing ART selection to improve persistence and reduce treatment switching remains an important consideration."

Journal • Medicare • Reimbursement • US reimbursement • Human Immunodeficiency Virus • Infectious Disease

Modeling the Long-Term Bone Health Impact of TDF/FTC PrEP in Adolescent MSM (ISPOR-EU 2025) - "This analysis underscores the need for effective PrEP options for adolescent MSM while considering long-term BMD consequences. This suggests the need for complementary interventions to minimize the impact on BMD or alternative PrEP options (including injectable CAB-LA PrEP with no observed impact on BMD from available short-term study data)."

Human Immunodeficiency Virus • Infectious Disease • Osteoporosis • Rheumatology

Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083. (PubMed, J Infect Dis) - "Consistent plasma CAB concentrations ≥4x PA-IC90 were estimated to provide 93% protection against HIV in MSM and TGW."

Journal • Human Immunodeficiency Virus • Infectious Disease

An Old Problem With a Re-purposed Solution: Novel Application of Emtricitabine-Tenofovir to Treat Persistent HBV Viremia (ACG 2025) - "Importantly, HBV DNA levels were consistently elevated with other NUC therapies across all cases, then became undetectable shortly after initiation of either FTC-TDF or FTC-TAF. Abbreviations: EMR (electronic medical records); ETV (Entecavir); FTC-TAF (Emtricitabine-Tenofovir Alafenamide); FTC-TDF (Emtricitabine-Tenofovir Disoproxil Fumarate); IU/mL (international units per milliliter); LDT (Telbivudine); LMV (Lamivudine); NUC (Nucleos(t)ide Analogues).​"

Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Liver Cirrhosis • Solid Tumor

Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study. (PubMed, Lancet HIV) - P3 | "Over 12 months of follow-up of infants, the DVR and oral PrEP were generally safe, with no composite adverse events related to study product. Together with available maternal safety data, this supports use of the DVR and oral PrEP by pregnant women to prevent HIV."

Clinical • Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease

Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084. (PubMed, J Int AIDS Soc) - "Given the comparable hormone concentrations between arms and the likely influence of the timing of sample collection on observed measurements, clinically significant interactions between CAB-LA and HC are not expected. Associations between F/TDF and hormone concentrations could not be effectively evaluated due to low adherence to F/TDF."

Clinical • Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

A RARE CONVERGENCE: METFORMIN-ASSOCIATED LACTIC ACIDOSIS AND DIABETIC KETOACIDOSIS IN SEPTIC SHOCK (CHEST 2025) - "Further history revealed that patient was on combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) for HIV pre-exposure prophylaxis. Early recognition of co-existence of MALA and DKA is crucial for appropriate management.Metformin toxicity should be considered in any patient with type 2 diabetes who presents with severe lactic acidosis, as prompt diagnosis can prevent mortality.MALA can occur in patients with previously normal renal function, particularly in presence of risk factors; sepsis and shock."

Acute Kidney Injury • Cardiovascular • Diabetes • Diabetic Nephropathy • Human Immunodeficiency Virus • Hypertension • Metabolic Disorders • Nephrology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Type 2 Diabetes Mellitus

Effects of Antiviral Therapies on Epstein-Barr Virus Replication (clinicaltrials.gov) - P2 | N=50 | Enrolling by invitation | Sponsor: Massachusetts General Hospital | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • CNS Disorders • Epstein-Barr Virus Infections • Multiple Sclerosis

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. (PubMed, J Infect Dis) - "Acquisition of HIV while receiving LEN and resistance to LEN in the context of unrecognized HIV was rare but associated with the emergence of the N74D LEN resistance-associated substitution in this population."

Journal • Human Immunodeficiency Virus • Infectious Disease

Unusual HIV seroconversion in PrEP user carrying heterozygous CCR5-Delta32 mutation: did he contract HIV? (EACS 2025) - "Prior to diagnosis, he received on-demand tenofovir/emtricitabine (TDF/FTC) PrEP with low adherence... These unusual HIV-1 seroreactivities on PrEP may be partly due to the CCR5-Delta32 heterozygous genotype that could confer lower pre-combined antiretroviral therapy (cART) HIV-1 RNA loads and delayed HIV-1 progression off cART. A multidisciplinary approach is crucial to face specific challenges."

Human Immunodeficiency Virus • Infectious Disease • CCR5 • CD4 • CD8

Antiretroviral Switch and Weight Gain: Cardiometabolic Implications of Switching to Darunavir/Cobicistat + Lamivudine (EACS 2025) - "We included males aged >18 years with adquire HIV, virological suppression for ≥6 months, and on a regimen of darunavir/cobicistat (DRV/c) plus tenofovir/emtricitabine (TDF/FTC). No significant changes in cardiovascular risk were observed. Metabolic alterations should be considered when selecting an antiretroviral regimen."

Human Immunodeficiency Virus • Infectious Disease

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men who have sex with men in a European country (EACS 2025) - "Sigmoidal curves: red(€21,088.5), yellow(€8,880), green(€4,320) Vertical lines; Black: GDP of Croatia; Red: GBP of Spain; Blue: GDP of Euro Zone, Yellow: GDP of Luxembourg. Conclusions : LEN could be cost-effective in Spain at a price of €4,320 per six-month dose."

Cost effectiveness • HEOR • Human Immunodeficiency Virus • Infectious Disease